Skip to main content

Featured

AI Anxiety and Metal Mayhem Shake U.S. Markets

U.S. stock futures stumbled as renewed doubts about the sustainability of the artificial‑intelligence boom rippled through financial markets. Tech-heavy benchmarks led the decline, with Nasdaq futures sliding and the S&P 500 also moving lower as investors reassessed whether AI-linked valuations have run too far, too fast. The unease wasn’t limited to equities. Precious metals experienced dramatic intraday swings, with gold and silver both whipsawing after a period of rapid gains. Traders pointed to shifting expectations around interest rates and safe‑haven demand as key drivers behind the volatility. The combination of tech-sector skepticism and commodity turbulence has created a tense backdrop for markets. While some investors see the pullback as a healthy reset, others worry it may signal deeper concerns about the durability of the recent rally. Markets now look ahead to upcoming economic data and corporate earnings for clearer direction.
Post a Comment
Read more

article

Labels

Alzheimer’s vaccines get a boost from new drug approval

 

After decades of disappointment and controversy, the field of Alzheimer’s disease research has finally seen a breakthrough with the approval of the first drug that targets the underlying pathology of the condition. 

Aducanumab, a monoclonal antibody that clears amyloid plaques from the brain, was granted accelerated approval by the US Food and Drug Administration in June 2021, despite mixed results from clinical trials and objections from some experts. 

The drug’s approval has rekindled interest in other therapeutic approaches that aim to prevent or slow down the progression of Alzheimer’s, such as vaccines that stimulate the immune system to attack amyloid or tau, another protein that accumulates in the brains of people with the disease. 

Several vaccine candidates are currently in various stages of development and testing, and some researchers are optimistic that they could offer a more effective and convenient way to treat Alzheimer’s than infusions of antibodies.


Labels:

Comments

Post a Comment